WAIKOLOA, Hawaii — Real-world, 12-month results demonstrated efficacy, safety and durability for faricimab as a treatment for retinal vein occlusion, according to a speaker at Retina 2026.
In light of faricimab’s approval for retinal vein occlusion in 2023, its widespread adoption has yielded opportunities to investigate its real-world impact on larger patient populations, Durga Borkar, MD, MMCi, said during a presentation.
“FARETINA-RVO is a retrospective, real-world study that leverages data from the American Academy of Ophthalmology’s IRIS registry,” Borkar said. “To be included in this